To include your compound in the COVID-19 Resource Center, submit it here.

Ganitumab: Phase II data

Data from 142 evaluable patients with wild-type K-Ras mCRC in the double-blind Phase II portion of a Phase Ib/II trial showed Vectibix panitumumab plus AMG 102

Read the full 262 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE